Anidulafungin compared with fluconazole therapy in critically ill patients

被引：0
|
作者：
DH Kett
AF Shorr
AC Reboli
AC Reisman
P Biswas
HT Schlamm
机构：
[1] University of Miami/Jackson Memorial Hospital,
[2] Washington Hospital Center,undefined
[3] University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School,undefined
[4] Pfizer Inc.,undefined
来源：
Critical Care | / 14卷 / Suppl 1期
关键词：
Public Health; Emergency Medicine; Retrospective Analysis; Initial Treatment; Fluconazole;
D O I：
10.1186/cc8304
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis
    Perez Civantos, D. V.
    Robles Marcos, M.
    Azanza Perea, J. R.
    Pazos Pacheco, C.
    Garcia-Montoto Perez, F.
    Jerez Gomez-Coronado, V.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 86 : 142 - 146
  • [2] Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive CandidiasisFocus on Critically Ill Patients
    Annette C. Reboli
    Coleman Rotstein
    Daniel H. Kett
    Michael Maschio
    Shannon Cartier
    Richard Chambers
    Miriam Tarallo
    PharmacoEconomics, 2011, 29 : 705 - 717
  • [3] Low but Sufficient Anidulafungin Exposure in Critically Ill Patients
    van Wanrooy, Marjolijn J. P.
    Rodgers, Michael G. G.
    Uges, Donald R. A.
    Arends, Jan P.
    Zijlstra, Jan G.
    van der Werf, Tjip S.
    Kosterink, Jos G. W.
    Alffenaar, Jan-Willem C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 304 - 308
  • [4] Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis Focus on Critically Ill Patients
    Reboli, Annette C.
    Rotstein, Coleman
    Kett, Daniel H.
    Maschio, Michael
    Cartier, Shannon
    Chambers, Richard
    Tarallo, Miriam
    PHARMACOECONOMICS, 2011, 29 (08) : 705 - 717
  • [5] Pharmacokinetic evaluation of fluconazole in critically ill patients
    Sinnollareddy, Mahipal
    Peake, Sandra L.
    Roberts, Michael S.
    Playford, E. Geoffrey
    Lipman, Jeffrey
    Roberts, Jason A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (11) : 1431 - 1440
  • [6] Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration
    Aguilar, Gerardo
    Ramon Azanza, Jose
    Carbonell, Jose A.
    Ferrando, Carlos
    Badenes, Rafael
    Asuncion Parra, Maria
    Sadaba, Belen
    Navarro, David
    Puig, Jaume
    Minana, Amanda
    Garcia-Marquez, Carlos
    Gencheva, Gergana
    Gutierrez, Andrea
    Marti, Francisco J.
    Javier Belda, F.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (06) : 1620 - 1623
  • [7] Limited-Sampling Strategies for Anidulafungin in Critically Ill Patients
    van Wanrooy, Marjolijn J. P.
    Proost, Johannes H.
    Rodgers, Michael G. G.
    Zijlstra, Jan G.
    Uges, Donald R. A.
    Kosterink, Jos G. W.
    van der Werf, Tjip S.
    Alffenaar, Jan-Willem C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) : 1177 - 1181
  • [8] Pharmacokinetics of anidulafungin in pleural effusion and ascites of critically ill patients
    Welte, R.
    Lorenz, I.
    Eller, P.
    Joannidis, M.
    Bellmann, R.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2017, 112 (04) : 399 - 399
  • [9] Pharmacokinetics of Anidulafungin in Critically Ill Patients with Candidemia/Invasive Candidiasis
    Liu, Ping
    Ruhnke, Markus
    Meersseman, Wouter
    Paiva, Jose Artur
    Kantecki, Michal
    Damle, Bharat
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) : 1672 - 1676
  • [10] Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
    Ruhnke, M.
    Paiva, J. A.
    Meersseman, W.
    Pachl, J.
    Grigoras, I.
    Sganga, G.
    Menichetti, F.
    Montravers, P.
    Auzinger, G.
    Dimopoulos, G.
    Borges Sa, M.
    Miller, P. J.
    Marcek, T.
    Kantecki, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (07) : 680 - 687
12345